Spyre Therapeutics, Inc. (SYRE)
NASDAQ
79.90
-0.95 (-1.18%)
Closed
Oct 8, 2026
Day's Range
77.0580.91
52 wk Range
16.04110.17
Financial Statements - SYRE - Spyre Therapeutics, Inc.
Revenue
0
Net Income
-155.20M▲ 25.4%
EBITDA
-229.56M▼ 10.1%
Free Cash Flow
-169.25M▼ 7.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 886K | 2.32M | 18.73M | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -219.56M | -208.56M | -128.56M | -84.78M | -65.64M | -81.48M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 39.45M | -20.71M | -216.39M | -7K | -122K | -5K |
| Pre Tax Income | -155.21M | -207.96M | -338.81M | -83.95M | -65.66M | -80.89M |
| Income Tax | -15K | 51K | -26K | -136K | 141K | 0 |
| Net Income | -155.20M | -208.01M | -338.79M | -83.81M | -65.80M | -80.89M |
| EPS Basic | -1.98 | -3.18 | -13.76 | -24.75 | -25 | -38 |
| EPS Diluted | -1.98 | -3.18 | -13.76 | -24.75 | -25 | -38 |
| Basic Shares Outstanding | 64.05M | 47.02M | 7.34M | 3.37M | 2.62M | 2.13M |
| Diluted Shares Outstanding | 64.05M | 47.02M | 7.34M | 3.37M | 2.62M | 2.13M |
| Ebit | -219.56M | -208.56M | -128.56M | -84.78M | -65.64M | -81.48M |
| Ebitda | -229.56M | -208.56M | 69.44M | -83.21M | -64.07M | -80.48M |
| Net Income Continuous Operations | -155.20M | -208.01M | -338.79M | -83.81M | -65.80M | -80.89M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
